Patent · US Active

Anti-CXCL13 antibodies

US11028164B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignee

I-MAB BIOPHARMA US LIMITED · US

Inventors

Haijuan Gu · Shanghai, CN
Qiumei Yang · Shanghai, CN

Key dates

Filing date	Sep 18, 2019
Grant date	Jun 8, 2021
Priority date	—
Expiry date	Sep 18, 2039

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/521
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL 13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.